Uterine fibroids affect a wide cross-section of the population, with prevalence, symptom
severity, and overall disease burden generally higher among black women, likely due to …

Background Uterine fibroids occur in up to 40% of women aged over 35 years. Some are
asymptomatic, but up to 50% cause symptoms that warrant therapy. Symptoms include …

Background Uterine fibroids are hormone-responsive neoplasms that are associated with
heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist …

OBJECTIVE: To investigate the noninferiority of relugolix compared with leuprorelin acetate
in reducing heavy menstrual bleeding associated with uterine leiomyomas. METHODS: In a …

Uterine fibroids are the most common gynecological disorder, classically requiring surgery
when symptomatic. Although attempts at finding a nonsurgical cure date back to centuries, it …

One in four women suffers from uterine leiomyomas (ULs)—benign tumours of the uterine
wall, also known as uterine fibroids—at some point in premenopausal life. ULs can cause …

Management of Uterine Fibroids - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter …

OBJECTIVE: To investigate the safety and efficacy of elagolix, an oral gonadotropin-
releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in …

Objective To evaluate the influence of 25-hydroxyvitamin D and transforming growth factor
β3 (TGF-β3) serum concentrations, weight, and family history on the risk of developing …

Background Uterine fibroids are smooth muscle tumours arising from the uterus. These
tumours, although benign, are commonly associated with abnormal uterine bleeding, bulk …